Oncology Medical News about breast cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer
Cancer, 06/04/09

Saphner T et al. - In a study to explore the association of nonalcoholic steatohepatitis (NASH) and tamoxifen in pts with breast cancer, it was found that NASH was present in 24 of 1105 pts with breast cancer (2.2%). Seven pts had NASH before they were diagnosed with breast cancer, and 17 pts developed NASH after their diagnosis. NASH was associated with use of tamoxifen and improved when tamoxifen was stopped.

Methods

Records of pts registered in St. Vincent Hospital Cancer Registry of Green Bay Wisconsin from January 1, 1992 to December 31, 2000 were reviewed.

Results

1105 pts with breast cancer were evaluated for NASH, and 24 cases of NASH were documented (2.2%).
7 pts had NASH before their diagnosis of breast cancer, and 17 pts developed NASH after their diagnosis of breast cancer.
In multivariate analysis, factors associated with NASH were tamoxifen use, body mass index (BMI), and age.
NASH improved after tamoxifen was stopped.
After discontinuation of tamoxifen, transaminase levels returned to normal in 14 of 16 pts.

<< Previous
Hospital I.T. Spending Surge Predicted

Next >>
Expression of ER-α36, a novel variant of estrogen...